Silvia Radenkovic, Anna N Ligezka, Sneha S Mokashi, Karen Driesen, Lynn Dukes-Rimsky, Graeme Preston, Luckio F Owuocha, Leila Sabbagh, Jehan Mousa, Christina Lam, Andrew Edmondson, Austin Larson, Matthew Schultz, Pieter Vermeersch, David Cassiman, Peter Witters, Lesa J Beamer, Tamas Kozicz, Heather Flanagan-Steet, Bart Ghesquière, Eva Morava
Abnormal polyol metabolism is predominantly associated with diabetes, where excess glucose is converted to sorbitol by aldose reductase (AR). Recently, abnormal polyol metabolism has been implicated in phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG) and an AR inhibitor, epalrestat, proposed as a potential therapy. Considering that the PMM2 enzyme is not directly involved in polyol metabolism, the increased polyol production and epalrestat's therapeutic mechanism in PMM2-CDG remained elusive...
May 23, 2023: Cell reports medicine